I just glanced through both papers what I got out of it is that cholesterol can alter binding affinity to some degree. It was already known that lower levels of cholesterol will reduce binding levels of ligands and CCR5 blockers. CCR5 blockade increases HDL cholesterol and lowers LDL cholesterol. Is the cholesterol they're talking about one or the other or either one?

If there is an increase in cholesterol you would see an increase in binding affinity. A decrease you'd see a decrease. Either way the greater the receptor occupancy by leronlimab the less binding of inflammatory ligands. At 700mg it's 100% RO across the board.